{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:41:51Z","timestamp":1764121311103,"version":"3.46.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA233414"],"award-info":[{"award-number":["T32CA233414"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007184","name":"YALE UNIVERSITY SCHOOL OF MEDICINE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["N01-PC-35136","N01-PC-35139"],"award-info":[{"award-number":["N01-PC-35136","N01-PC-35139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","award":["U55\/CCR921930-02","N02-PC-15105"],"award-info":[{"award-number":["U55\/CCR921930-02","N02-PC-15105"]}],"id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005002","name":"California Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017683","name":"Frederick A. DeLuca Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100159","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:35:50Z","timestamp":1755624950000},"page":"100159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-4174","authenticated-orcid":false,"given":"Rong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-0579","authenticated-orcid":false,"given":"Jessica M.","family":"Stempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Neparidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2617","authenticated-orcid":false,"given":"Mengyang","family":"Di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-2877","authenticated-orcid":false,"given":"Lourdes","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-778X","authenticated-orcid":false,"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bneo.2025.100159_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bneo.2025.100159_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100159_bib3","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome\u2013negative myeloproliferative neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"10.1016\/j.bneo.2025.100159_bib4","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100159_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.2015.233","article-title":"The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours","volume":"113","author":"Thomas","year":"2015","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2025.100159_bib6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2025.100159_bib7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bneo.2025.100159_bib8","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100159_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2025.100159_bib10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/bloodadvances.2022008259","article-title":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea","volume":"7","author":"Wang","year":"2023","journal-title":"Blood Adv"},{"year":"2023","series-title":"Jakafi (ruxolitinib) tablets, for oral use. Package insert","key":"10.1016\/j.bneo.2025.100159_bib11"},{"issue":"17","key":"10.1016\/j.bneo.2025.100159_bib12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100159_bib14","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1080\/10428194.2016.1195501","article-title":"Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence","volume":"57","author":"Harrison","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.bneo.2025.100159_bib15","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2025.100159_bib16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.bneo.2025.100159_bib17","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100159_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100159_bib19","first-page":"508","article-title":"Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib","volume":"16","author":"Blechman","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100159_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archdermatol.2010.25","article-title":"Sun, drugs, and skin cancer: a continuing saga","volume":"146","author":"Turner","year":"2010","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100159_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.2023022345","article-title":"Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib","volume":"143","author":"Rampotas","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bneo.2025.100159_bib22","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1182\/bloodadvances.2019000646","article-title":"Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients","volume":"3","author":"Maffioli","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bneo.2025.100159_bib23","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s00277-021-04647-0","article-title":"Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies","volume":"100","author":"Sekhri","year":"2021","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100159_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100159_bib25","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.bneo.2025.100159_bib26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100159_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10428194.2019.1688323","article-title":"Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis","volume":"61","author":"Tremblay","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.bneo.2025.100159_bib28","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100159_bib29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100159_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"year":"2019","series-title":"Inrebic (fedratinib) capsules, for oral use. Package insert","key":"10.1016\/j.bneo.2025.100159_bib32"},{"year":"2022","series-title":"Vonjo (pacritinib) capsules, for oral use. Package insert","key":"10.1016\/j.bneo.2025.100159_bib33"},{"year":"2023","series-title":"Ojjaara (momelotinib) tablets, for oral use. Package insert","key":"10.1016\/j.bneo.2025.100159_bib34"},{"issue":"7","key":"10.1016\/j.bneo.2025.100159_bib35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"8","key":"10.1016\/j.bneo.2025.100159_bib36","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"10.1016\/j.bneo.2025.100159_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.bneo.2025.100159_bib38","first-page":"81","article-title":"Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.bneo.2025.100159_bib39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100159_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428194.2015.1071492","article-title":"Risk of second primary malignancies and survival of adult patients with polycythemia vera: a United States population-based retrospective study","volume":"57","author":"Khanal","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.bneo.2025.100159_bib41","first-page":"1197","article-title":"A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database","volume":"57","author":"Brunner","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.bneo.2025.100159_bib42","doi-asserted-by":"crossref","first-page":"E368","DOI":"10.1016\/S2352-3026(18)30108-X","article-title":"Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden","volume":"5","author":"Chattopadhyay","year":"2018","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100159_bib43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.leukres.2015.05.002","article-title":"Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: clinical characteristics, therapy and outcome","volume":"39","author":"Masarova","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.bneo.2025.100159_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106770","article-title":"Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval","volume":"112","author":"Thomas","year":"2022","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.bneo.2025.100159_bib45","doi-asserted-by":"crossref","first-page":"e13043","DOI":"10.1111\/dth.13043","article-title":"Nonmelanoma skin cancer associated with Hydroxyurea treatment: overview of the literature and our own experience","volume":"32","author":"Cantisani","year":"2019","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.bneo.2025.100159_bib46","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100159_bib47","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100159_bib48","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100159_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"13","key":"10.1016\/j.bneo.2025.100159_bib51","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/cncr.34195","article-title":"Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea","volume":"128","author":"Alvarez-Larr\u00e1n","year":"2022","journal-title":"Cancer"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:40:35Z","timestamp":1764121235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000949"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100159","relation":{},"ISSN":["2950-3280"],"issn-type":[{"type":"print","value":"2950-3280"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100159"}}